Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts
Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts Benzinga
Covered in this story
Analyst targets on Johnson & Johnson
- RBC Capital Markets: $255 → $290 by Oct 2027 · Outperform via Investing.com
- Bank of America: $265 → $278 by Sep 2027 · Neutral via AOL.com
- UBS: $275 → $320 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $JNJ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Johnson & Johnson →Dalsna Finance is currently tracking 38 stories mentioning Johnson & Johnson, the earliest published 25 Sept 2026.
Summary aggregated from Benzinga's public RSS feed. The full reporting belongs to Benzinga — please read it on their site.